Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This readout could boost Tryngolza’s standing in its potential rivalry with Arrowhead’s Redemplo in severe ...

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune. The reorganisation at the ...

When drugmakers look to build out certain therapeutic areas, there are two options: Create your own and buy someone else’s. For Stockholm-based Sobi, getting a leg up in hematology meant making an ...

Rare disease specialist Swedish Orphan Biovitrum (Sobi) has posted strong growth for the first quarter of the year, led by its haemophilia franchise. The company markets Elocta, a recombinant clotting ...

Sobi announces positive topline results from pivotal phase 3 REDUCE 2 study of pozdeutinurad in gout: Stockholm, Sweden Saturday, May 23, 2026, 11:00 Hrs [IST] Sobi, a global biop ...

CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

(RTTNews) - Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK) said that it has streamlined nirsevimab contractual arrangements. Nirsevimab economics simplified through a new royalty agreement with Sanofi ...

florio ITP empowers patients to take control of their ITP and better advocate for their care; the florio ITP app is the only ITP app available in the United States that is free for both patients and ...